

Adamas Pharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 25-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Registered..... 11

 Phase 3 Clinical..... 20

 Discovery..... 27

[Return to Table of Contents](#)

Adamas Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Adamas Pharmaceuticals Inc
Parent Company Name	Adamas Pharmaceuticals Inc
Website	http://adamaspharma.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	8
Number of Patents as Owner	18
Number of Patents as Third Party	2
Number of Deals	5
Key Indications	Fatigue, Movement disorder, Parkinsons disease, Alzheimers disease, Traumatic brain injury, Unidentified indication, Brain injury, Neurological disease, Sleep disorder, Glaucoma, HIV associated dementia, Hepatitis C virus infection, Neuropathic pain, Respiratory syncytial virus infection
Key Target-based Actions	NMDA receptor antagonist, Inosine monophosphate dehydrogenase inhibitor, Influenza matrix protein 2 inhibitor, Acetylcholinesterase inhibitor, Exo-alpha sialidase inhibitor, Folate antagonist, Nitric oxide synthase inhibitor
Key Technologies	Small molecule therapeutic, Drug combination, Oral formulation, Capsule formulation, Sustained release formulation, Oral sustained release formulation, Intravenous formulation, Systemic formulation unspecified, Quick release formulation, Controlled release formulation, Formulation preservation, Tablet formulation

COMPANY PROFILE

SUMMARY

Adamas Pharmaceuticals (formerly NeuroMolecular Pharmaceuticals Inc), headquartered in Emeryville, CA, was founded in 2004 and is focused on the development of controlled release, novel small molecule therapeutics called advantaged therapeutics for neurological like Alzheimer's diseases and dementia and infectious diseases like influenza.

FINANCIAL

In April 2014, Adamas priced its IPO of 3 million common stock shares at \$16 each. The underwriters were granted a 30-day over-allotment option to purchase up to an additional 450,000 common stock shares. At that time, shares were expected to begin trading on the NASDAQ Global Market under the ticker symbol 'ADMS' on April 10, 2014 and the offering was expected to close on April 15, 2014; later that month, the offering was closed and net proceeds from the offering was estimated to be approximately \$41.5 million; later that month, the company issued 81,371 additional shares to the underwriters pursuant to the over-allotment option and raised net proceeds of approximately \$42.7 million. And the shares had begun trading on NASDAQ.

In August 2009, the company raised \$40 million from a series D financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	4	6
Infectious disease	0	3	3
Respiratory disease	0	2	2
Degeneration	1	1	2
Unidentified indication	1	1	2
Injury	1	0	1
Fatigue	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Registered	1
Phase 3 Clinical	1
Discovery	1
Discontinued	1
No Development Reported	7

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	2	0	0	0	2
Drug - CRADA	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	1	0	1

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	3	5
Infectious disease	0	2
Respiratory disease	0	2

Trials by Phase

Phase	Ongoing	All
Phase 3	3	4
Phase 2	0	3
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Gastrointestinal disease	2	0	2
Growth disorder	1	0	1
Degeneration	5	0	5
Immune disorder	6	0	6
Psychiatric disorder	5	0	5
Musculoskeletal disease	1	0	1
Ocular disease	2	0	2
Genetic disorder	1	0	1
Metabolic disorder	1	0	1

[Return to Table of Contents](#)



Neurological disease	17	0	17
Respiratory disease	5	0	5
Infectious disease	5	0	5
Injury	2	0	2
Toxicity and intoxication	2	0	2
Inflammatory disease	2	0	2
Fatigue	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis **SNAPSHOT**

Drug Name	memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis
Key Synonyms	Namzaric;Arimenda
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc;Actavis plc
Inactive Companies	Forest Laboratories Inc
Highest Status	Registered
Active Indications	Alzheimers disease
Target-based Actions	Acetylcholinesterase inhibitor;NMDA receptor antagonist
Other Actions	Nootropic agent;Neuroprotectant
Technologies	Oral formulation;Capsule formulation;Small molecule therapeutic;Oral sustained release formulation;Drug combination
Last Change Date	23-Apr-2015

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis **DEVELOPMENT PROFILE**

SUMMARY

Adamas Pharmaceuticals, in collaboration with US licensee Actavis following its acquisition of Forest Laboratories, has developed a once-daily, fixed-dose combination of an extended-release form of memantine hydrochloride ER (Namenda XR) and donepezil hydrochloride, as Namzaric (MDX-8704). In the US, the drug is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. In ex-US territories, the drug is being developed as ADS-8704,, .

In December 2014, the drug was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type; at that time, Actavis expected to launch the product in the US in 2Q15 .

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis **DEVELOPMENT STATUS**

CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Actavis plc	Alzheimers disease	US	Registered	24-Dec-2014
Adamas Pharmaceuticals Inc	Alzheimers disease	US	Registered	24-Dec-2014


[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Alzheimers disease	EU	Phase 3 Clinical	31-Dec-2013

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis CHEMICAL STRUCTURES


CAS Registry Number:	Confidence Level:
	1
	
Name	Type
Balaxur	Trade Name
Arimenda	Trade Name
Acrescent	Trade Name
MDX-8704	Research Code
ADS-8704	Research Code
memantine hydrochloride + donepezil hydrochloride	

CAS Registry Number:	Confidence Level:
120014-06-4	1
	
Name	Type
donepezil	BAN; INN
NAL-8812	Research Code
NAL-8817	Research Code

[Return to Table of Contents](#)

Name	Type
donepezil	BAN; INN
NAL-8812	Research Code
NAL-8817	Research Code

CAS Registry Number:	Confidence Level:
19982-08-2	1






Name	Type
memantine	BANN; INN
D-145	Research Code
memantine ER	

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis DRUG NAMES

Names	Type
memantine hydrochloride + donepezil hydrochloride	
Namzaric	Trade Name
ADS-8704	Research Code
Arimenda	Trade Name
Namenda XR + donepezil (extended release formulation, dementia), Adamas/ Actavis	
memantine ER + donepezil (extended release formulation, dementia), Adamas/Forest	
memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis	
MDX-8704	Research Code
Namenda XR + donepezil (extended release formulation, dementia), Adamas/ Forest	

[Return to Table of Contents](#)

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation,
CHARTS



[Return to Table of Contents](#)

COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Actavis, following its acquisition of Forest Laboratories are presented. No Consensus forecast data for Adamas Pharmaceuticals are currently available.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In November 2012, Forest and Adamas entered into an agreement for the development and commercialization of Arimenda to treat moderate to severe dementia of the Alzheimer's type in the US. Forest and Adamas would collaborate on the drug's development, and Forest would have exclusive US commercialization rights [1340659]. In July 2014, Actavis acquired Forest [1574106].

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Dementia											
0	0	0	1	0	0	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	1	0	0	0	0	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia),
Adamas/Actavis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Adamas Pharmaceuticals Inc	1	0	0	0	1
Actavis plc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table


Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart

Chart displayed by Owner/Third Party




[Return to Table of Contents](#)

Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Actavis plc	3	0	3
Adamas Pharmaceuticals Inc	3	1	3
Sun Pharmaceutical Industries Ltd	1	1	2
Suntory Ltd	1	0	1
Teva Pharmaceutical Industries Ltd	1	1	1
Upsher-Smith Laboratories Inc	1	0	1
Lupin Ltd	1	0	1
Adamis Pharmaceuticals Corp	1	0	1
Synthon BV	0	1	1
Wockhardt Ltd	1	1	1
Orchid Chemicals & Pharmaceuticals Ltd	1	0	1
Dr Reddy's Laboratories Ltd	1	0	1
Amneal Pharmaceutical LLC	1	0	1
Interpharm Pharmaceutical Products Inc	0	1	1
Chemo Iberica SA	0	1	1
Neurobiological Technologies Inc	1	0	1
Mylan Inc	1	0	1
Merz & Co GmbH	1	0	1
neuraxpharm Arzneimittel GmbH & Co	0	1	1
H Lundbeck A/S	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	3
New use	1
Product	1

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas SNAPSHOT

Drug Name	amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas
Key Synonyms	Nurelin;amantadine
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Movement disorder;Fatigue;Traumatic brain injury
Target-based Actions	
Other Actions	Antiparkinsonian;Neuroprotectant;Nootropic agent
Technologies	Oral formulation;Capsule formulation;Small molecule therapeutic;Sustained release formulation
Last Change Date	10-Apr-2015

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEVELOPMENT PROFILE

SUMMARY

Adamas Pharmaceuticals is developing ADS-5102 (Nurelin), a fixed-dose, once-nightly, extended-release capsule formulation of amantadine for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD), and the company is also investigating the drug for the potential treatment of fatigue associated with PD and multiple sclerosis (MS), and traumatic brain injury (TBI) . In July 2011, a phase II/III trial was initiated for LID in PD patients; in June 2013, positive data were reported ; later that month, full data were presented ; in October 2014, another phase III trial was initiated in the US and Europe and at that time, the company expected to complete enrollment in all studies in 2015. In July 2012, the drug was listed as being in pre-IND development for TBI and MS fatigue. In May 2014, the drug was expected to enter phase II/III development for TBI. In August 2014, the company expected to make a NDA filing in the first half of 2016 if the phase III registration trial is successful. In January 2015, the company planned to initiate clinical development for hypokinetic movement disorders, hyperkinetic movement disorders or neuropsychiatric disorders. In March 2011, the company was seeking for commercialization rights in the US and other ex-US markets.

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Movement disorder	Europe	Phase 3 Clinical	28-Oct-2014
Adamas Pharmaceuticals Inc	Movement disorder	US	Phase 3 Clinical	18-Jul-2011


[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Fatigue	US	Discovery	04-Jun-2012
Adamas Pharmaceuticals Inc	Traumatic brain injury	US	Discovery	05-Jul-2012


amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas
CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
768-94-5	2



Name	Type
amantadine	INN
ADS-5102	

CAS Registry Number:	Confidence Level:
	2



Name	Type
amantadine hydrochloride	USAN
Nurelin	Trade Name
ADS-5101	Research Code

[Return to Table of Contents](#)

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DRUG NAMES

Names	Type
Nurelin	Trade Name
ADS-5102	
amantadine	INN
amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas	
amantadine (extended release formulation, Parkinsons disease/movement disorder), Adamas	

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Movement disorder											
0	0	3	3	0	1	0	0	0	0	3	4
Parkinsons disease											
0	0	1	1	0	1	0	0	0	0	1	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	3	3	0	1	0	0	0	0	3	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Catalent Pharma Solutions	1	0	0	0	1
Adamas Pharmaceuticals Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Adamas Pharmaceuticals Inc	3	0	3

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
Product	1
New use	1
Product (derivative)	1

[Return to Table of Contents](#)

ADS-9000

ADS-9000 SNAPSHOT

Drug Name	ADS-9000
Key Synonyms	
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	15-Dec-2014

ADS-9000 DEVELOPMENT PROFILE

SUMMARY

Adamas is investigating ADS-9000 series, as a single agent or combination therapy, for the potential treatment of unspecified indication. In December 2014, the program was in research and at that time, the company was planning to conduct phase II trials.

ADS-9000 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Unidentified indication	US	Discovery	10-Dec-2014

ADS-9000 DRUG NAMES

Names	Type
ADS-9000	Research Code

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

